Personnel change: Asia Pacific pharmaceutical intends to remove the post of military director!

Asia Pacific Pharmaceutical (002370) issued "independent opinions of independent directors on matters related to the 19th meeting of the 6th board of directors of the company", and agreed to propose to the general meeting of shareholders to remove the post of military director According to the announcement, in view of Ren Jun, a director of the company, who was the chairman and general manager of Shanghai Xinfeng biomedical Co., Ltd and Shanghai xinshengyuan Pharmaceutical Group Co., Ltd (hereinafter referred to as "Shanghai xinshengyuan"), a wholly-owned subsidiary of the company, failed to perform the normal decision-making procedures for external guarantee matters of the company, provided guarantee for others without authorization, and Ren Jun was supervised and managed by China Securities According to the company law of the people's Republic of China, the articles of association, the guidelines for the standardized operation of listed companies on the SME Board of Shenzhen Stock Exchange and other relevant provisions, Ren Jun is no longer suitable to continue to serve as a director of a listed company, and agrees to request the general meeting of shareholders to remove him According to the data, Ren Jun was elected as a director of the sixth board of directors at the 2016 annual general meeting of shareholders of Asia Pacific pharmaceutical on May 16, 2017, with the original term of office ending on May 15, 2020 As of January 7, Ren Jun held 10949934 shares in Asia Pacific pharmaceutical and Cao Lei, his spouse, held 6333522 shares in the company Asia Pacific pharmaceutical said that the procedures for removing directors of military companies comply with relevant laws and regulations Adorable adorable